INDV (Indivior Pharmaceuticals Inc) Stock Financials & Earnings

INDVIndivior Pharmaceuticals Inc

Mkt Cap$4B

Revenue (TTM)$1.2B

Net Income (TTM)$210M

EPS (TTM)$1.64

Free Cash Flow (TTM)-$86M

Gross Margin80.3%

Op. Margin24.4%

Net Margin16.9%

FCF Margin-6.9%

P/S Ratio (TTM)3.4x

P/E Ratio (TTM)19.8x

YoY Rev Growth+4.3%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$253M	$214M	$57M
Q2 23	$276M	$226M	$61M
Q3 23	$271M	$225M	-$183M
Q4 23	$293M	$242M	$61M
Q1 24	$284M	$246M	$75M
Q2 24	$299M	$220M	-$118M
Q3 24	$307M	$238M	$4M
Q4 24	$299M	$276M	$96M
Q1 25	$266M	$222M	$66M
Q2 25	$302M	$250M	$72M
Q3 25	$314M	$230M	$43M
Q4 25	$358M	$294M	$122M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$27M	$78M	$53M	—
Q2 23	$32M	$75M	$58M	—
Q3 23	$18M	$390M	—	—
Q4 23	$29M	$89M	$68M	—
Q1 24	$28M	$77M	$67M	—
Q2 24	$26M	$152M	—	—
Q3 24	$22M	$208M	—	—
Q4 24	$31M	—	$255M	—
Q1 25	$22M	$65M	$67M	—
Q2 25	$21M	$158M	—	—
Q3 25	$33M	—	—	$155M
Q4 25	$17M	—	—	$155M

Revenue Segments

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$588M	$117M	$705M
Q2 23	$592M	$97M	$689M
Q3 23	$610M	$112M	$722M
Q4 23	$316M	$94M	$410M
Q1 24	$248M	$82M	$330M
Q2 24	$302M	$77M	$379M
Q3 24	$288M	$30M	$318M
Q4 24	$319M	$1M	$320M
Q1 25	$372M	$1M	$373M
Q2 25	$510M	$0	$510M
Q3 25	$445M	$0	$445M
Q4 25	$195M	$0	$195M

Shares Outstanding

Revenue Per Employee

Revenue / Employee